Suchen
Karyopharm Therapeutics Inc
KPTIZur Watchlist hinzufügen
9.600USD
+0.050+0.52%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
175.79MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Karyopharm Therapeutics Inc Unternehmen
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Karyopharm Therapeutics Inc Informationen
BörsenkürzelKPTI
Name des UnternehmensKaryopharm Therapeutics Inc
IPO-datumNov 06, 2013
CEOPaulson (Richard A)
Anzahl der mitarbeiter279
WertpapierartOrdinary Share
GeschäftsjahresendeNov 06
Addresse85 Wells Avenue
StadtNEWTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02459
Telefon16176580600
Websitehttps://karyopharm.com/
BörsenkürzelKPTI
IPO-datumNov 06, 2013
CEOPaulson (Richard A)
Führungskräfte von Karyopharm Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
85.25K
+0.51%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
16.41K
+94.47%
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
15.51K
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
15.51K
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
15.51K
--
Dr. Zhen Su
Dr. Zhen Su
Independent Director
Independent Director
15.51K
--
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
13.01K
+4.14%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
12.50K
+3.94%
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
85.25K
+0.51%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
16.41K
+94.47%
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
15.51K
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
15.51K
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
15.51K
--
Dr. Zhen Su
Dr. Zhen Su
Independent Director
Independent Director
15.51K
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Karyopharm Therapeutics Inc?
Die fünf größten Anteilseigner von Karyopharm Therapeutics Inc sind: Mr. Michael Mano, J.D.
Wie viele Institutionen halten Anteile an Karyopharm Therapeutics Inc (KPTI)?
Mit Stand vom 2026Q1 halten 236 Institutionen Anteile an Karyopharm Therapeutics Inc, mit einem Gesamtmarktwert von etwa 14.10M, was 62.56% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 5055019.00 gestiegen.